CytRx touts survival data after aldoxorubicin hold lifted
This article was originally published in Scrip
Executive Summary
CytRx has shared updates for more than a year from the Phase IIb soft tissue sarcoma (STS) clinical trial for aldoxorubicin, a modified version of the chemotherapy agent doxorubicin, but the company's stock traded flat on 22 January after CytRx reported a 1.6-month overall survival benefit in the trial.